National Accutane Registry Begins Taking Names

A national registry of Accutane users began accepting names on December 30, 2005. The iPLEDGE program, intended to keep track of persons currently using the anti-acne drug, requires health care providers and pharmacists to identify all patients who have been prescribed and/or sold Accutane, or any generic version of the drug (isotretinoin). The goal of the registry is to reduce the incidence of pregnancy-related harm caused by the drug, including birth defects and birth injuries.